- Home
- ZTEK vs BYSI Comparison
ZTEK vs BYSI Comparison
Compare ZTEK & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | BYSI |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 58.4M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | BYSI |
|---|---|---|
| Price | $0.46 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 272.8K | 22.9K |
| Earning Date | 02-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $1.18 |
| 52 Week High | $1.24 | $2.44 |
Technical Indicators
Market Signals| Indicator | ZTEK | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 37.09 |
| Support Level | $0.46 | $1.39 |
| Resistance Level | $0.55 | $1.60 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 49.79 | 3.24 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.